Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/1999

01-02-1999

Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’

Authors: Romano Demicheli, Rosalba Miceli, Cristina Brambilla, Laura Ferrari, Angela Moliterni, Milvia Zambetti, Pinuccia Valagussa, Gianni Bonadonna

Published in: Breast Cancer Research and Treatment | Issue 3/1999

Login to get access
Metadata
Title
Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’
Authors
Romano Demicheli
Rosalba Miceli
Cristina Brambilla
Laura Ferrari
Angela Moliterni
Milvia Zambetti
Pinuccia Valagussa
Gianni Bonadonna
Publication date
01-02-1999
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/1999
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006134702484

Other articles of this Issue 3/1999

Breast Cancer Research and Treatment 3/1999 Go to the issue

OriginalPaper

Diet and risk for breast cancer recurrence and survival

OriginalPaper

Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis

OriginalPaper

Tamoxifen and risk of large bowel cancer in women with breast cancer

OriginalPaper

Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients

OriginalPaper

Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland

OriginalPaper

Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits